Psilocybin reduces symptoms in treatment resistant depression, trial results show.
No abstract is available for this record.
Bibliographic context
- Journal
- BMJ
- Date
- 2022-11-01
- Source
- Europe PMC
- PubMed
- 36411539
Topics and keywords
Citation graph
0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.
Indexed papers citing this DOI
Related papers
Contribution of the Serotonin 5-HT2A Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat StressNeuropsychopharmacology Reports · 2026-08-31Modeled Long-Term Effects of Psilocybin on Dynamic Activity and Effective Connectivity of Fronto-Striatal-Thalamic Circuits.Human Brain Mapping · 2026-06-30Psilocybin reduces fear memory and restores neuroplasticity in the hippocampus and medial prefrontal cortex.Journal of Psychopharmacology · 2026-06-27Blocking 5-HT2B receptors abolishes psilocybin’s efficacy in the rat forced swim testJournal of Psychopharmacology · 2026-06-22Psilocybin-assisted therapy in treatment-resistant depression: rapid remission, uncertain durability, and the next phase of clinical evidenceAnnals of Medicine and Surgery · 2026-06-17Psilocybin and Mental Health Outcomes: Scoping Review with ☸SAIMSARASAIMSARA Journal · 2026-06-14Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depressionJournal of Affective Disorders · 2026-06-03Psilocybin shows mixed results for patients with treatment-resistant depressionThe Brown University Psychopharmacology Update · 2026-05-28